In Russia will shorten the time to market of the drug from COVID-19 " Favipiravir ", which is currently undergoing clinical test, research of the drug will continue after its registration, said Last news in the press service of the Ministry of health.
currently in Russia, the drug "Favipiravir" is not registered, only patients with COVID-19 that participate in clinical trials, said the press service.
the Ministry told that the expected total duration of studies is six to 12 months.
This will enable us to greatly reduce the time to market of a medicinal product, concluded the Ministry of health.
in March, the Supervisory Board of RDIF blessed the development of a joint venture with the group of companies "Chemrar" for production of medicinal preparation " Favipiravir ", according to Chinese experts, effective in the battle with coronavirus, and another anti-virus innovative medicines, as well as among them based on it.
research of the drug is approved in Russia throughout Russia, with the participation of 330 patients. According to the head of the Russian direct investment Fund Kirill Dmitriev, he demonstrated its effectiveness.
"at the end of the first 60 patients in 6 centres, we are witnessing a very important statistic that says that 60% of patients receiving the drug, already on the fifth day of therapy have a negative test for the coronavirus," said he.
yesterday it was announced that the drug for the treatment of coronavirus COVID-19, which will produce a joint venture of the RDIF and a group of " Khimrar ", expected to release with the name " Avidavit ".
The latest information on the situation of COVID-19 in Russia and the world presented on the portal stopmanager. Of the Russian Federation.